Aptamers are short, single-stranded oligonucleotides (DNA or RNA) that bind to specific targets (proteins, small molecules, cells) with high affinity and specificity. Their generation has traditionally been dominated by the SELEX (Systematic Evolution of Ligands by EXponential enrichment) process. However, this method has significant limitations, driving innovation toward non-SELEX approaches. 1. Current Predominant Method: SELEX SELEX is an iterative, in vitro selection-amplification process with several variations, each suited for different targets and applications. Core Steps of SELEX: Library Creation: A random oligonucleotide library (10¹³–10¹⁵ sequences) flanked by fixed primer sites. Incubation & Binding: Library exposed to the target. Partitioning: Separation of target-bound sequences from unbound ones. Amplification: PCR (DNA) or RT-PCR (RNA) of bound sequences. Repetition: Typically 8–15 cycles to enrich high-affinity binders. Cloning & Sequencing: Identification of enriched aptamer candidates. Key Variations of SELEX: Cell-SELEX: Uses whole cells as targets, ideal for biomarker discovery. Capture-SELEX: For small molecules, using immobilized targets. Capillary Electrophoresis-SELEX (CE-SELEX): High-efficiency partitioning via electrophoresis. Microfluidic-SELEX: Reduces time and reagent use via automation. Magnetic Bead-Based SELEX: Easy separation using target-coated beads. Limitations of SELEX: Time-Consuming: Multiple cycles take weeks to months. Labor-Intensive: Requires significant hands-on effort. Amplification Bias: PCR can favor certain sequences unrelated to binding. Limited Sequence Diversity: Early high-affinity binders can dominate, reducing diversity. Cost: High reagent and time costs. 2. Emerging Trend: Non-SELEX Approaches…
Excellent choice! Aptamer Screening is the core process for discovering these synthetic, single-stranded DNA or RNA molecules that bind to a specific target with high affinity and specificity. It's often called SELEX (Systematic Evolution of Ligands by EXponential enrichment). Here’s a comprehensive breakdown of aptamer screening, from concept to modern advancements. 1. The Core Principle: SELEX The traditional screening method is an in vitro Darwinian evolutionary process. The basic cycle is repeated until a pool of high-affinity aptamers is obtained. Key Steps: Library Design: Start with a vast random-sequence oligonucleotide library (10^13 - 10^15 different molecules). Each molecule has a central random region (20-60 nucleotides) flanked by constant primer regions for PCR amplification. Incubation: The library is incubated with the target molecule (e.g., a protein, small molecule, cell). Partitioning: Unbound sequences are washed away. Bound sequences (potential aptamers) are retained. This is the most critical step, dictating the success of the entire screen. Elution: The bound sequences are recovered (e.g., by heating, denaturing agents, or target digestion). Amplification: The recovered sequences are amplified by PCR (for DNA) or RT-PCR (for RNA) to create an enriched pool for the next round. Iteration: Steps 2-5 are repeated (typically 5-15 rounds) under increasingly stringent conditions (e.g., shorter incubation time, more washes, competitive agents) to select…
Ribosome Display is a cell-free (in vitro) display technology used to evolve and select peptides or proteins by keeping a physical connection between phenotype (the translated peptide/protein) and genotype (the encoding mRNA). Instead of relying on a living host (as in phage or yeast display), ribosome display uses a stalled translation complex so that the newly made polypeptide remains associated with the ribosome, which in turn remains associated with its mRNA—forming a non-covalent ternary complex that can be selected for binding or function. 1) What Ribosome Display Is (And Why the mRNA Link Matters) Display technologies work best when every “candidate molecule” can be traced back to the genetic information that produced it. In ribosome display, this tracking is achieved by stabilizing a complex often described as: nascent polypeptide – ribosome – mRNA Because the polypeptide and its mRNA remain physically connected through the ribosome, any selection step that enriches for a desired function (for example, binding to a target) can be followed by recovery of the encoding mRNA, conversion to cDNA, and amplification—creating an iterative loop of evolution entirely in vitro. 2) Core Mechanism: How the Ribosome “Holds” the Peptide to the mRNA The stalled translation complex…
1) What “Bacterial Display” Means (and Why It Matters) Bacterial Display (also called bacterial surface display) is a protein/peptide engineering method where a bacterium is genetically programmed to present a peptide (or protein fragment) on its outer surface, while the DNA encoding that peptide remains inside the same cell. This physically links phenotype (binding/function) to genotype (the encoding sequence), enabling efficient discovery and optimization of peptides from large libraries. 2) Core Principle: Surface Presentation + High-Throughput Selection A typical bacterial display workflow looks like this: Build a peptide library Create DNA encoding millions of peptide variants (often randomized regions) and clone them into a plasmid or genomic locus. Fuse peptides to a “surface scaffold” The library peptides are genetically fused to a bacterial surface-localized protein (the scaffold) so they are exported and exposed externally. Common scaffold classes include outer membrane proteins, autotransporters, fimbriae/flagella, and engineered systems like circularly permuted outer membrane proteins used for peptide display. Expose library cells to a target The target might be a purified protein, a receptor domain, a small molecule conjugate, or even whole cells (depending on the goal). Select the winners Enriched cells are collected using methods like FACS (fluorescence-activated cell sorting)…
Yeast Display (also called Yeast Surface Display, YSD) is a protein engineering and screening technology that presents peptides or proteins on the outside surface of yeast cells, effectively turning each yeast cell into a “living bead” that physically links a displayed molecule (phenotype) to its encoding DNA inside the cell (genotype). This makes it especially powerful for building and screening peptide libraries to discover binders, optimize affinity, and study molecular interactions. 1) What “Yeast Display” Means in Practice In yeast display, researchers genetically fuse a peptide (or protein) to a yeast surface-anchor system so that the peptide is exported through the secretory pathway and tethered to the cell wall. A classic and widely used anchoring strategy in Saccharomyces cerevisiae is the Aga1p–Aga2p system, where a fusion partner (often Aga2p) helps attach the displayed peptide to the cell surface, while the encoding plasmid remains inside the same cell. This one-cell-one-variant format is what makes library screening so efficient. 2) Why Yeast Is a Strong Host for Display Libraries Yeast is a eukaryote, so it can support more complex folding and quality control than many prokaryotic systems. For many peptide/protein scaffolds, this can translate into improved display of properly folded…
mRNA Display is an in vitro selection and directed-evolution technology that physically couples a peptide (or protein) to the mRNA sequence that encodes it through a covalent bond. This genotype–phenotype “fusion” allows researchers to screen enormous molecular libraries and then recover the winning sequences by amplification, enabling fast, iterative optimization under tightly controlled experimental conditions. 1) The Core Idea: Genotype–Phenotype Coupling Without Cells Every selection technology needs a reliable way to keep “what a molecule does” attached to “the information that made it.” In mRNA Display, that attachment is literal: the newly made peptide becomes covalently linked to its own mRNA, producing a stable fusion that survives stringent washing and enrichment steps. This is a major conceptual advantage over systems where the linkage is non-covalent or depends on living cells for propagation. Because the entire workflow is performed in vitro, the experimenter can tune conditions (buffers, salts, temperature, denaturants, competitors) to match the target biology and the selection pressure they want to apply. 2) How the Covalent Link Is Formed: Puromycin at the 3′ End The “magic” reagent behind classic mRNA Display is puromycin, a molecule that mimics the 3′ end of an aminoacyl-tRNA. When puromycin is physically…
We possess particular expertise in developing aptamers for a wide range of complex protein targets—such as membrane proteins, kinases, cytokines, and antibodies. By optimizing screening strategies, we overcome challenges that are difficult to resolve with traditional methods, delivering highly specific aptamers with performance comparable to or even surpassing that of monoclonal antibodies. For small molecules—including hormones, toxins, and antibiotics—we employ unique library construction and screening technologies. These effectively address the challenge of limited epitopes in small-molecule targets, providing clients with key recognition elements for applications in small-molecule detection, environmental monitoring, food safety, and beyond.
We offer one-stop peptide screening services, ranging from library design and high-throughput screening to functional validation. Leveraging our diverse peptide libraries (including random libraries, phage display libraries, cyclic peptide libraries, etc.), we can rapidly identify functional peptides with high affinity and specificity for specific targets. These peptide molecules hold broad application potential in areas such as drug lead compound development, cell-penetrating peptides, and core raw materials for diagnostic reagents.
In molecular biology and biotherapeutic design, specificity refers to a peptide’s ability to bind only to its intended target while avoiding interactions with unrelated molecules. This property is a cornerstone of precision medicine, enabling researchers to create compounds that influence biological processes with minimal unintended effects. What Specificity Means in Peptide–Target Interactions Specificity arises from the precise arrangement of a peptide’s amino acids. These structural features allow the peptide to recognize a unique three-dimensional pattern—such as a receptor pocket, an exposed protein domain, or a biochemical motif—on its target. Even minor variations in peptide shape, charge distribution, or hydrophobic patterns can dramatically alter the binding profile. This molecular “fit” principle ensures that effective peptides interact only with their designated targets. Why Specificity Matters in Research and Therapeutic Development High specificity offers several critical advantages in scientific and clinical applications: Reduced Off-Target Effects When a peptide binds only to its intended molecule, the likelihood of unintended interactions decreases, improving safety and reliability. Enhanced Experimental Clarity Researchers can interpret results more accurately because the peptide affects a single biological component. Improved Drug Precision Therapeutic peptides with strong specificity can modulate disease-related pathways without disturbing healthy tissues, supporting the development of…
Affinity—commonly described as the strength of binding between a peptide and its biological target—is a foundational concept in molecular biology, biochemistry, drug discovery, and biomedical engineering. For researchers, clinicians, and biotechnology developers, understanding affinity helps predict how effectively a peptide can recognize, bind, and influence a specific molecule within complex biological systems. This article provides a clear, search-optimized, and fully original explanation of affinity, how it is measured, and why it matters. What Is Affinity? Affinity refers to the quantitative strength of the interaction between a peptide and its target, such as a protein, receptor, enzyme, or other biomolecule. When a peptide binds strongly to its target, the system is said to have high affinity; when the binding is weak or transient, it exhibits low affinity. In molecular terms, affinity represents the balance between: Association (binding) Dissociation (unbinding) A high-affinity interaction favors stable attachment, often requiring only a small amount of peptide to achieve effective binding. Why Affinity Matters in Peptide Science 1. Precision in Drug Design Peptide-based therapeutics rely heavily on affinity to determine: How well a peptide recognizes a disease-related target Whether the binding is strong enough to produce a therapeutic effect…